Is there a benefit from lycopene supplementation in men with prostate cancer? A systematic review (Q37630360)

21 August 2017

1 reference

title

Is there a benefit from lycopene supplementation in men with prostate cancer? A systematic review (English)

1 reference

21 August 2017

1 reference

1 reference

F Haseen

1 reference

21 August 2017

M M Cantwell

series ordinal

1 reference

21 August 2017

J M O'Sullivan

series ordinal

1 reference

21 August 2017

L J Murray

series ordinal

1 reference

21 August 2017

language of work or name

1 reference

1 September 2009

1 reference

Prostate Cancer and Prostatic Diseases

21 August 2017

published in

1 reference

21 August 2017

1 reference

21 August 2017

1 reference

21 August 2017

page(s)

325-332

1 reference

Lycopene: a novel drug therapy in hormone refractory metastatic prostate cancer

21 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.38

Prostate carcinogenesis in N-methyl-N-nitrosourea (NMU)-testosterone-treated rats fed tomato powder, lycopene, or energy-restricted diets

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.38

Complementary and alternative therapies in prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.38

A population-based survey of complementary and alternative medicine use in men recently diagnosed with prostate cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.38

Total and specific complementary and alternative medicine use in a large cohort of men with prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.38

Supplement use among men with prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.38

Frequent use of complementary medicine by prostate cancer patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.38

Unconventional medicine in the United States. Prevalence, costs, and patterns of use

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.38

Zinc supplement use and risk of prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.38

Tomatoes, tomato-based products, lycopene, and cancer: review of the epidemiologic literature

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.38

Intake of carotenoids and retinol in relation to risk of prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.38

Plasma and dietary carotenoids, and the risk of prostate cancer: a nested case-control study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.38

Carotenoids and gene regulation.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.38

Lycopene and 1,25-dihydroxyvitamin D3 cooperate in the inhibition of cell cycle progression and induction of differentiation in HL-60 leukemic cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.38

Lycopene is a more potent inhibitor of human cancer cell proliferation than either alpha-carotene or beta-carotene

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.38

Lycopene interferes with cell cycle progression and insulin-like growth factor I signaling in mammary cancer cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.38

Diverse carotenoids protect against chemically induced neoplastic transformation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.38

Serum and tissue lycopene and biomarkers of oxidation in prostate cancer patients: a case-control study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.38

Does tomato consumption effectively increase the resistance of lymphocyte DNA to oxidative damage?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.38

Chemoprevention of prostate cancer through dietary agents: progress and promise

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.38

Progress in prostate cancer chemoprevention: modulators of promotion and progression

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.38

Diet after diagnosis and the risk of prostate cancer progression, recurrence, and death (United States).

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.38

Diet and dietary supplement intervention trials for the prevention of prostate cancer recurrence: a review of the randomized controlled trial evidence

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.38

Assessing the quality of reports of randomized clinical trials: is blinding necessary?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.38

Effects of lycopene supplementation in patients with localized prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.38

Tomato sauce supplementation and prostate cancer: lycopene accumulation and modulation of biomarkers of carcinogenesis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.38

Lycopene inhibits DNA synthesis in primary prostate epithelial cells in vitro and its administration is associated with a reduced prostate-specific antigen velocity in a phase II clinical study.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.38

Oxidative DNA damage in prostate cancer patients consuming tomato sauce-based entrees as a whole-food intervention.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.38

A tomato-based, lycopene-containing intervention for androgen-independent prostate cancer: results of a Phase II study from the North Central Cancer Treatment Group

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.38

Phase I-II prospective dose-escalating trial of lycopene in patients with biochemical relapse of prostate cancer after definitive local therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.38

Effects of tomato sauce consumption on apoptotic cell death in prostate benign hyperplasia and carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.38

A comparison of lycopene and orchidectomy vs orchidectomy alone in the management of advanced prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.38

The natural history of clinical prostate carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.38

The use of PSA as biomarker in nutritional intervention studies of prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.38

cis-trans isomers of lycopene and beta-carotene in human serum and tissues

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.38

Effect of lycopene on insulin-like growth factor-I, IGF binding protein-3 and IGF type-I receptor in prostate cancer cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.38

Concentrations of Selected Carotenoids and Vitamin A in Human Liver, Kidney and Lung Tissue

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.38

Carotenoid and tocopherol composition of human adipose tissue

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.38

Prooxidant-antioxidant shift induced by androgen treatment of human prostate carcinoma cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.38

Models of DNA structure achieve almost perfect discrimination between normal prostate, benign prostatic hyperplasia (BPH), and adenocarcinoma and have a high potential for predicting BPH and prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.38

Lycopene: a biologically important carotenoid for humans?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.38

Suppression by carotenoids of microcystin-induced morphological changes in mouse hepatocytes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.38

Thirteen-week oral toxicity study of synthetic lycopene products in rats

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.38

Developmental (embryo-fetal toxicity/teratogenicity) toxicity studies of synthetic crystalline lycopene in rats and rabbits

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.38

Carotenoid Content of Thermally Processed Tomato-Based Food Products

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.38

Uptake of lycopene and its geometrical isomers is greater from heat-processed than from unprocessed tomato juice in humans

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.38

Lycopene is more bioavailable from tomato paste than from fresh tomatoes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.38

Chronic ingestion of lycopene-rich tomato juice or lycopene supplements significantly increases plasma concentrations of lycopene and related tomato carotenoids in humans

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.38

Bioavailability and in vivo antioxidant properties of lycopene from tomato products and their possible role in the prevention of cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.38

31 March 2020

Identifiers

DOI

10.1038/PCAN.2009.38

1 reference

21 August 2017

1 reference